Core Insights - Cytiva released the "2025 Global Biopharmaceutical Index" at the 10th Pharmaceutical Innovation and Investment Conference, aimed at helping decision-makers understand industry trends and develop resilient strategies to drive innovation [1][3] Industry Overview - This is the third release of the index since its inception in 2021, based on in-depth surveys of 1,250 biopharmaceutical executives across 22 countries, evaluating performance across six dimensions: supply chain resilience, manufacturing agility, R&D ecosystem, talent pool, policy and regulation, and newly added sustainability [3][4] - The global biopharmaceutical industry score for 2025 has slightly decreased compared to 2023, highlighting the need for the industry to address the gap between innovation and market access to benefit patients more quickly [3][4] Challenges Faced by the Industry - The report identifies four major challenges: 1. Bottlenecks in academia-industry collaboration, with nearly half of respondents struggling to find high-quality partners, particularly in CROs, CDMOs, academic institutions, and government labs [4] 2. Talent shortages in new therapy areas, with 38% of respondents indicating a lack of specialized talent in cell and gene therapy, mRNA, ADCs, and bispecific antibodies, as well as significant gaps in sustainability, digitalization, and AI talent [4] 3. Inconsistencies and lack of innovation in regulatory frameworks, with about half of respondents noting a lack of coherence in policies, and a quarter stating that traditional approval processes do not match the complexity of new therapies [4] 4. Supply chains being more susceptible to geopolitical influences, with over 70% of respondents believing that fluctuations in tariffs and trade policies will significantly impact procurement strategies in the coming year, leading over 60% to expand regional or local sourcing and promote domestic production to enhance supply chain security [4] Strategic Initiatives - Cytiva's president in China emphasized that the index serves as both a health check for the industry and a guide for action, with plans to leverage global industry experience and local capabilities through end-to-end solutions, a comprehensive talent development system, and the "Sail Plan" to support the global reach of Chinese innovations [7] - The "Sail Plan," initiated this year, focuses on addressing core challenges for Chinese innovative drugs going abroad, providing professional support across key areas from source innovation, international regulatory compliance, outbound strategies, to global business expansion, aiming to transition the Chinese biopharmaceutical industry from following to leading [7]
《2025全球生物制药指数》发布 揭示行业四大挑战与机遇
Sou Hu Cai Jing·2025-10-27 12:30